EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

This study is testing a combination of two drugs — an EZH2 inhibitor (tulmimetostat) and an immunotherapy drug that blocks PD-1 — in patients with advanced non-small cell lung cancer who have already tried immunotherapy but whose cancer kept growing. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of advanced non-small cell lung cancer - Your cancer has progressed after platinum-based chemotherapy, immunotherapy, or a combination of both - You have already received at least 2 doses of an anti-PD-1/PD-L1 immunotherapy drug and your cancer still progressed - You have at least one measurable tumor site - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have certain serious infections or uncontrolled conditions - You have specific autoimmune or organ-related conditions that make immunotherapy unsafe - Your cancer has not previously been treated with immunotherapy Talk to your doctor to see if this trial is right for you.